Questcor Pharmaceuticals (NASDAQ:QCOR)
A pharmaceutical company that focuses on novel therapeutics for the treatment of diseases and disorders of the central nervous system.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
WillSurfForFood
(92.51)
Submitted: 2/1/2012 5:32:24 PM :
Start Price:
$35.17
QCOR Score:
+1.71
streetsweaper
Recs
EnigmaDude
(98.87)
Submitted: 1/20/2012 3:39:10 PM :
Start Price:
$36.25
QCOR Score:
-5.78
I read the questions asked by StreetSweeper's "editor" (lambaster) and Questcor's responses and I see nothing to indicate that the company is engaged in any unethical or illegal activities. Yet another attempt to provide "news" so the StreetSweeper folks can profit from shorting the stock.
Read for yourself:
http://finance.yahoo.com/news/Questcor-Pharmaceuticals-prnews-3875109327.html?x=0
Recs
wil2ein
(< 20)
Submitted: 1/12/2012 12:28:13 PM :
Start Price:
$34.15
QCOR Score:
-1.51
This stock is undervalued right now, Recent drop-off was an overreaction and it will bounce.
Recs
Maximix
(< 20)
Submitted: 11/25/2011 9:29:33 AM :
Start Price:
$41.26
QCOR Score:
-30.62
Excellent medical reports on the efficacy
of QCOR's exclusive Multiple Sclerosis drug in several
advanced situations
Sales and profits are rising significantly.
Qcor also has a great pipeline for future
growrth
A comfortable investment in these hectic times.
Recs
SnowBawl
(< 20)
Submitted: 10/23/2011 5:11:04 AM :
Start Price:
$34.74
QCOR Score:
-7.46
#1 best small public company.
Recs
Jonock
(< 20)
Submitted: 9/28/2011 11:17:42 AM :
Start Price:
$27.84
QCOR Score:
+10.92
Popular with the speculators
Recs
tbonci
(66.48)
Submitted: 8/26/2011 1:12:40 PM :
Start Price:
$27.75
QCOR Score:
+12.40
The price is high on this company when looking at most metrics, but the growth, profitability, and returns are also consistently high.
Recs
GinaSB
(46.45)
Submitted: 8/11/2011 10:47:07 PM :
Start Price:
$31.44
QCOR Score:
-2.16
ROE = 30%
Total Debt to Equity = 0%
Positive growth
CEO seems like a good fit.
Seems poised for growth
Recs
NoDoughBro
(70.14)
Submitted: 7/27/2011 10:58:52 PM :
Start Price:
$32.32
QCOR Score:
+5.41
Missed the party again!
Recs
TripleTheMarket
(33.13)
Submitted: 6/2/2011 1:05:41 PM :
Start Price:
$22.89
QCOR Score:
+50.88
Momentum!
Recs
racingbold
(< 20)
Submitted: 5/24/2011 8:32:52 PM :
Start Price:
$22.18
QCOR Score:
+55.56
The new frontier for QCOR's flagship drug, Acthar, is the NS application. If phase IV testing proves out, Acthar could be a last line of defense treatment for NS patients before dialysis.
Recs
Radiohead101
(43.84)
Submitted: 1/25/2011 4:59:44 PM :
Start Price:
$15.75
QCOR Score:
+118.46
Emerging healthcare
Recs
houstcarr
(< 20)
Submitted: 1/7/2011 1:43:06 AM :
Start Price:
$15.42
QCOR Score:
-121.65
earnings miss
Recs
Maribaza
(30.48)
Submitted: 11/29/2010 6:52:29 PM :
Start Price:
$14.36
QCOR Score:
+129.85
81,81,83
85,91,99
Recs
subsurfacemapper
(72.82)
Submitted: 11/17/2010 12:39:34 AM :
Start Price:
$13.56
QCOR Score:
+144.45
Inside ownership over 10%, no debt, ROE of 39, long term growth est 31%. Screen result.
Recs
medisoft
(28.94)
Submitted: 9/8/2010 2:05:18 AM :
Start Price:
$9.71
QCOR Score:
+238.15
Its drug to treat insomnia is almost approved. It will be approved by FDA on September 11, and after that they can sell that drug to a lot of people. Also, their numbers are solid, with solid earnings and earnings growth, low PEG, very good ROE and ROA.
Recs
waitin4him
(31.35)
Submitted: 1/11/2010 8:33:26 AM :
Start Price:
$4.83
QCOR Score:
+607.88
No debt, priced well below value.
Recs
pcolajoe
(83.75)
Submitted: 7/19/2009 11:47:38 AM :
Start Price:
$5.65
QCOR Score:
+476.88
Good numbers, PM 42%, GM 92%, ROA 51%, ROE 67%. Strong break out in price, above 28 day MA and 100 day MA.
Recs
jbs4radio
(72.53)
Submitted: 6/16/2009 3:06:11 AM :
Start Price:
$4.51
QCOR Score:
+630.43
PEG = 0.29
Recs
Zhuren
(96.21)
Submitted: 6/3/2009 2:45:49 AM :
Start Price:
$4.43
QCOR Score:
+645.70
I hate making story stock picks, but this company is still growing, and is committed to shareholder value by buying stock back at these depressed levels. It's bargain priced if you expect its growth to continue, although it is dependent on US customers, which is a big negative in the years to come. But if the growth continues, it will at least kill the returns of the S&P500.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 43 : 1 2 3 Next »